Works matching IS 21623619 AND DT 2025 AND VI 14 AND IP 1

Results: 104
    1
    2
    3

    Incidence, mortality, and risk factors of bladder, kidney, prostate and testicular cancers in China and comparisons with the United States, the United Kingdom, Japan, and the Republic of Korea: an up-to-date overview based on the Global Burden of Disease 2021

    Published in:
    Experimental Hematology & Oncology, 2025, v. 14, n. 1, p. 1, doi. 10.1186/s40164-025-00694-9
    By:
    • Kadeerhan, Gaohaer;
    • Jiang, Zhongji;
    • Guo, Hong;
    • Ma, Xinzhi;
    • Zhang, Jin;
    • Guo, Wenmin;
    • Jia, Jiedong;
    • Gao, Yibo;
    • Wang, Dongwen
    Publication type:
    Article
    4
    5

    Targeting collagen to optimize cancer immunotherapy.

    Published in:
    Experimental Hematology & Oncology, 2025, v. 14, n. 1, p. 1, doi. 10.1186/s40164-025-00691-y
    By:
    • Wang, Yida;
    • Zhang, Feng;
    • Qian, Zhiwen;
    • Jiang, Ying;
    • Wu, Danping;
    • Liu, Lu;
    • Ning, Xin;
    • Mei, Jie;
    • Chen, Daozhen;
    • Zhang, Yan
    Publication type:
    Article
    6

    Targeted degradation of sICOSL reverses cytotoxic T cells dysfunction.

    Published in:
    Experimental Hematology & Oncology, 2025, v. 14, n. 1, p. 1, doi. 10.1186/s40164-025-00692-x
    By:
    • Wu, Zhenghao;
    • Zheng, Peng;
    • Qi, Ruobing;
    • Xiao, Yunxiao;
    • Xi, Zihan;
    • Dai, Lei;
    • Chen, Tao;
    • Wang, Qianheng;
    • Zhang, Furong;
    • Wang, Rong;
    • Tang, Zimei;
    • Zhao, Xiangwang;
    • Tan, Jie;
    • Ming, Jie;
    • Lei, Ping;
    • Liu, Chunping;
    • Huang, Tao
    Publication type:
    Article
    7
    8
    9
    10
    11

    Reduced morbidity and mortality of cGVHD in patients who received treatment with mesenchymal stromal cells for steroid-resistant aGVHD: long-term follow-up of a randomized phase 3 trial.

    Published in:
    Experimental Hematology & Oncology, 2025, v. 14, n. 1, p. 1, doi. 10.1186/s40164-025-00687-8
    By:
    • Zhao, Ke;
    • Lin, Ren;
    • Fan, Zhiping;
    • Li, Zhen;
    • Chen, Xiaoyong;
    • Xuan, Li;
    • Huang, Fen;
    • Xu, Na;
    • Wu, Xiuli;
    • Chen, Shaohua;
    • Sun, Jing;
    • Zhang, Xi;
    • Weng, Jianyu;
    • Li, Yonghua;
    • Li, Yuhua;
    • Lin, Dongjun;
    • Nie, Danian;
    • Wang, Shunqing;
    • Xu, Xiaojun;
    • Zhang, Xiaohui
    Publication type:
    Article
    12
    13
    14
    15
    16
    17
    18
    19
    20
    21
    22
    23
    24

    Correction: Lysin (K)-specific demethylase 1 inhibition enhances proteasome inhibitor response and overcomes drug resistance in multiple myeloma.

    Published in:
    2025
    By:
    • Bandini, Cecilia;
    • Mereu, Elisabetta;
    • Paradzik, Tina;
    • Labrador, Maria;
    • Maccagno, Monica;
    • Cumerlato, Michela;
    • Oreglia, Federico;
    • Prever, Lorenzo;
    • Manicardi, Veronica;
    • Taiana, Elisa;
    • Ronchetti, Domenica;
    • D'Agostino, Mattia;
    • Gay, Francesca;
    • Larocca, Alessandra;
    • Besse, Lenka;
    • Merlo, Giorgio Roberto;
    • Hirsch, Emilio;
    • Ciarrocchi, Alessia;
    • Inghirami, Giorgio;
    • Neri, Antonino
    Publication type:
    Correction Notice
    25
    26
    27
    28
    29
    30
    31
    32
    33
    34
    35
    36
    37
    38
    39
    40
    41
    42
    43

    Hypomagnesemia in lymphoma patients receiving CAR T therapy correlates with immune dysfunction and decreased survival.

    Published in:
    Experimental Hematology & Oncology, 2025, v. 14, n. 1, p. 1, doi. 10.1186/s40164-025-00623-w
    By:
    • Gile, Jennifer J.;
    • Mondello, Patrizia;
    • Wang, Zixing;
    • Li, Ying;
    • Bansal, Radhika;
    • Gandhi, Sangeetha;
    • Zhang, Henan;
    • Babadi, Elham;
    • Martinez, Kodi;
    • McCoy, Gabrielle;
    • Shao, Zuoyi;
    • Regan, Kevin;
    • Hathcock, Matthew A.;
    • Wang, Panwen;
    • Wang, Junwen;
    • Al Saleh, Abdullah S.;
    • Ruan, Gordon;
    • Ansell, Stephen M.;
    • Bennani, N. Nora;
    • Johnston, Patrick B.
    Publication type:
    Article
    44

    Hypomethylating agents plus venetoclax for high-risk MDS and CMML as bridge therapy to transplant: a GESMD study.

    Published in:
    Experimental Hematology & Oncology, 2025, v. 14, n. 1, p. 1, doi. 10.1186/s40164-025-00652-5
    By:
    • Zugasti, Ines;
    • Lopez-Guerra, Monica;
    • Castaño-Díez, Sandra;
    • Esteban, Daniel;
    • Avendaño, Alejandro;
    • Pomares, Helena;
    • Perez, Ana;
    • García-Ávila, Sara;
    • Conejo, Irene Padilla;
    • de la Fuente Montes, Cristina;
    • Martínez-Roca, Alexandra;
    • Merchán, Beatriz;
    • Jiménez-Vicente, Carlos;
    • Guijarro, Francesca;
    • Álamo, Jose Ramón;
    • Cortes-Bullich, Albert;
    • Torrecillas, Victor;
    • Mont, Lucia;
    • Carcelero, Esther;
    • Riu, Gisela
    Publication type:
    Article
    45
    46
    47
    48
    49
    50